Table 3.
Comparison of clobazam treated patients from the study by Sivakumar et al. and the present study
| Variable | Sivakumar et al. (n = 17) | Present study (n = 24) | P value |
|---|---|---|---|
| Age on admission, y | 63 (54–70) | 64 (52–72) | 0.466b |
| History of seizures | 11 (64.7) | 10 (41.7) | 0.146a |
| CLB maintenance dose (mg/d) | 20 (10–30) | 20 (14–23) | 0.763b |
| RSE duration before CLB, d | 4 (2–7) | 2 (0–9) | 0.432b |
| CLB last AED added to therapy | 16 (94.1) | 6 (25.0) | <0.001 a |
| Use of anesthetics | 12 (70.6) | 11 (45.8) | 0.116a |
| Length of hospital stay, d | 30 (17–38) | 29 (13–61) | 0.672b |
Values are n (%), or median (interquartile range); significant (p < 0.05) parameters are expressed in bold
Abbreviations: CLB clobazam, RSE refractory status epilepticus
aPearson χ2 test
bMann-Whitney U-test